Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate

NCT ID: NCT01601171

Last Updated: 2022-06-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2030-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The World Health Organization estimates approximately 10% of couples experience some sort of infertility problem.

In humans, puberty is the process through which we develop reproductive capacity.

The timing of puberty varies greatly in the general population and is influenced by both genetic and environmental factors. In extreme cases of pubertal delay, puberty progresses only partially or not at all and results in the clinical picture of congenital hypogonadotropic hypogonadism (CHH), either accompanied by anosmia in 50% of cases (Kallmann syndrome \[KS\]) or by normal sense of smell (nCHH), with a male: female ratio of 4:1.

CHH is due to GnRH deficiency (incidence 1: 4,000-10,000) and result in the failure of sexual maturation and infertility. It is genetically heterogeneous, with multiple patterns of inheritance and several associated loci. In the clinical spectrum of GnRH deficiency, CHH may also be associated with a cleft lip/palate (CL/P) in 5 to 7% of cases. However, this prevalence increases up to 40% in CHH patients carrying a mutation in a CL/P gene, suggesting a genetic overlap between CHH and CL/P.

Disorders of puberty have provided insight into the biology of reproduction and genetic technologies have enabled us to deepen understanding in this field. The focus of this study is to better understand the genetic control of puberty and human reproduction as well as its link with CL/P.

Increasing understanding of the molecular basis (genes) of inherited reproductive disorders and CL/P may enable investigators to:

* improve diagnostic testing and treatments for these problems
* develop new diagnostic tests and therapies for patients
* enhance counseling for patients and families with reproductive disorders
* enhance counseling for patients and families with cleft lip/palate

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kallmann Syndrome Hypogonadotropic Hypogonadism Hypothalamic Amenorrhea Polycystic Ovarian Syndrome Precocious Puberty Cleft Lip and Palate Cleft Palate Cleft Lip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Patients with reproductive disorders with or without cleft lip/palate will be recruited for:

* completion of medical questionnaire and review of medical records
* family tree (including questions on reproductive disorders and cleft lip/palate)
* specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy
* smell testing
* hearing test
* bone density
* brain MRI
* kidney, testicular/ovarian ultrasound

No interventions assigned to this group

Family members

Family members of Patients will be recruited for:

* completion of medical questionnaire
* specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy
* smell testing

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hypogonadotropic hypogonadism
* Kallmann syndrome
* adult-onset hypogonadotropic hypogonadism
* hypothalamic amenorrhea
* polycystic ovarian syndrome
* primary gonadal failure
* precocious puberty
* cleft lip/palate
* family members of the above groups

Exclusion Criteria

* acute illness/hospitalization
* pituitary tumors
* iron overload (hemochromatosis)
* infiltrative diseases (sarcoidosis)
* chronic alcohol abuse
* illicit drug use
* anabolic steroid abuse
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swiss National Science Foundation

OTHER

Sponsor Role collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nelly Pitteloud

Professor of Medicine, Chief of Service

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nelly Pitteloud, M.D.

Role: PRINCIPAL_INVESTIGATOR

Centre Hositalier Universitaire Vaudois (CHUV)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Canton of Vaud, Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emmanuelle Paccou

Role: CONTACT

+41 79 556 60 13

Michela Adamo, MD

Role: CONTACT

+41 079 556 85 14

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Emmanuelle Paccou

Role: primary

+41 79 556 60 13

Michela Adamo, MD

Role: backup

+41 079 556 85 14

References

Explore related publications, articles, or registry entries linked to this study.

Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, Beenken A, Clarke J, Pers TH, Dworzynski P, Keefe K, Niedziela M, Raivio T, Crowley WF Jr, Seminara SB, Quinton R, Hughes VA, Kumanov P, Young J, Yialamas MA, Hall JE, Van Vliet G, Chanoine JP, Rubenstein J, Mohammadi M, Tsai PS, Sidis Y, Lage K, Pitteloud N. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet. 2013 May 2;92(5):725-43. doi: 10.1016/j.ajhg.2013.04.008.

Reference Type RESULT
PMID: 23643382 (View on PubMed)

Villanueva C, Jacobson-Dickman E, Xu C, Manouvrier S, Dwyer AA, Sykiotis GP, Beenken A, Liu Y, Tommiska J, Hu Y, Tiosano D, Gerard M, Leger J, Drouin-Garraud V, Lefebvre H, Polak M, Carel JC, Phan-Hug F, Hauschild M, Plummer L, Rey JP, Raivio T, Bouloux P, Sidis Y, Mohammadi M, de Roux N, Pitteloud N. Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. Genet Med. 2015 Aug;17(8):651-9. doi: 10.1038/gim.2014.166. Epub 2014 Nov 13.

Reference Type RESULT
PMID: 25394172 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.chuv.ch/edm/edm_home/edm-recherche/edm-research-groups/edm-researchgroup-pitteloud.htm

Web page for the Principal Investigator Nelly Pitteloud's research group

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

345/11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FaceBase Biorepository
NCT01252264 COMPLETED